Patents by Inventor Douglas J. M. Allen
Douglas J. M. Allen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7297682Abstract: This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-?-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.Type: GrantFiled: May 6, 2004Date of Patent: November 20, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Robert J. Rafka, Colman B. Ragan, Douglas J. M. Allen
-
Patent number: 6861412Abstract: This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-o-methyl-4-C-[(propylamino)methyl]-?-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.Type: GrantFiled: August 12, 2002Date of Patent: March 1, 2005Assignee: Pfizer, Inc.Inventors: Robert J. Rafka, Colman B. Ragan, Douglas J. M. Allen
-
Publication number: 20040152758Abstract: The instant invention provides crystal forms of 5-chloro-N-[(1S,2R)-3-[3R,4S]-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide (I) 1Type: ApplicationFiled: October 22, 2003Publication date: August 5, 2004Applicant: Pfizer Inc.Inventors: Douglas J. M. Allen, Frank R. Busch, Joseph F. Krzyzaniak, Zheng Jane Li, Susan L. Orrill, Peter R. Rose, Derek L. Tickner, Harry O. Tobiassen
-
Patent number: 6683106Abstract: The instant invention provides crystal forms of 5-chloro-N-[(1S,2R)-3-[3R,4S]-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenyl) methyl)propyl]-1H-indole-2-carboxamide (I) processes for the production of such crystal forms; pharmaceutical compositions comprising such crystal forms; and methods of treating glycogen phosphorylase dependent diseases, or conditions with such crystal forms, or such pharmaceutical compositions.Type: GrantFiled: April 15, 2003Date of Patent: January 27, 2004Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Frank R. Busch, Joseph F. Krzyzaniak, Zheng Jane Li, Susan L. Orrill, Peter R. Rose, Derek L. Tickner, Harry O. Tobiassen
-
Publication number: 20030195243Abstract: The instant invention provides crystal forms of 5-chloro-N-[(1S,2R)-3-[3R,4S]-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide (I) 1Type: ApplicationFiled: April 15, 2003Publication date: October 16, 2003Applicant: Pfizer Inc.Inventors: Douglas J. M. Allen, Frank R. Busch, Joseph F. Krzyzaniak, Zheng Jane Li, Susan L. Orrill, Peter R. Rose, Derek L. Tickner, Harry O. Tobiassen
-
Patent number: 6583274Abstract: Novel crystalline forms of a compound of Formula 1 are disclosed: Also disclosed are pharmaceutical compositions comprising these forms, and methods of their preparation and use.Type: GrantFiled: May 2, 2000Date of Patent: June 24, 2003Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Barry J. Morton, Robert J. Rafka, Colman B. Ragan
-
Publication number: 20030092642Abstract: This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-0-methyl-4-C-[(propylamino)methyl]-&agr;-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-&bgr;-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.Type: ApplicationFiled: August 12, 2002Publication date: May 15, 2003Inventors: Robert J. Rafka, Colman B. Ragan, Douglas J. M. Allen
-
Patent number: 6465437Abstract: This invention relates to a novel crystalline diphosphate salt of (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(propylamino)methyl]-&agr;-L-ribo-hexopryanosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-&bgr;-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one that is useful as an antibacterial and antiprotozoal agent in mammals. This invention also relates to pharmaceutical compositions containing the free base of the diphosphate salt and the methods of treating bacterial and protozoal infections in mammals by administering the free base of the diphosphate to mammals requiring such treatment. The free base of the diphosphate salt of the present invention possesses potent activity against various bacterial and protozoal infections when given by parenteral application to mammals.Type: GrantFiled: May 18, 2000Date of Patent: October 15, 2002Assignee: Pfizer Inc.Inventors: Robert J. Rafka, Colman B. Ragan, Douglas J. M. Allen
-
Patent number: 6436987Abstract: The present invention provides novel polymorphic forms of anhydrous crystalline (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid, hereinafter compound (I), and a novel salt, and a hydrate of said compound, wherein each novel composition has particular characteristics that contribute to its use in pharmaceutical formulations. The novel monohydrate of compound (I) is described, which can be advantageously isolated from water wet solvents and formulated via wet granulation techniques. The novel ethylene diamine (mono) salt is also described, and demonstrates superior solubility and bioavailability. Additionally, polymorphic forms A and B of anhydrous crystalline compound (I) are described, wherein form A has superior thermal stability, and form B has superior solubility.Type: GrantFiled: March 13, 2001Date of Patent: August 20, 2002Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Nancy A. Sage, David B. Joseph
-
Patent number: 6268489Abstract: Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.Type: GrantFiled: December 21, 1992Date of Patent: July 31, 2001Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Kevin M. Nepveux
-
Patent number: 6262067Abstract: Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo(2.2.2]Octyl-3-yl)-(5-iso-propyl-2-methoxybenzyl)amine dihydrochloride dihydrate are Form I and Form II. The pharmaceutical composition containing at least are of these polymorphs has advantageous stability for formulation to treat emesis in patients receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule or intravenous. A method of making Forms I and II is also disclosed.Type: GrantFiled: May 4, 2000Date of Patent: July 17, 2001Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Troy Anthony Appleton, Michael Jon Gumkowski, David Joseph Muehlbauer, Timothy Norris
-
Patent number: 6239141Abstract: This invention relates to suspensions for oral administration comprising novel trovafloxacin zwitterionic crystals, and processes for preparing such crystals. This invention further relates to other pharmaceutical compositions comprising these novel crystals, and to methods of using these suspensions, and these novel crystals in such other dosage forms, for treating bacterial infections in mammals.Type: GrantFiled: May 5, 2000Date of Patent: May 29, 2001Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Daniel R. Arenson, S. Sonja Sekulic
-
Patent number: 6194585Abstract: The present invention relates to the process for preparing a compound of the formula wherein A is C1-C6 alkyl, an aryl which is mono or disubstituted with F, Cl, Br, OCH3, C1-C3 alkyl or benzy. In the preferred compound A is CH3. The 5-lipoxygenase inhibitors that are prepared in accordance with the present invention are selective inhibitors of the action of lipoxygenase enzyme and are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals.Type: GrantFiled: August 24, 1999Date of Patent: February 27, 2001Assignee: Pfizer Inc.Inventors: Charles Kwon-Fung Chiu, Ravi Mysore Shankar, Douglas J. M. Allen
-
Patent number: 6080756Abstract: The invention relates to a monohydrate polymorph PII.M of a compound of the formula ##STR1## exhibiting the following X-ray powder diffraction pattern______________________________________ Peak No. 1 2 3 4 5 6 7 8 ______________________________________ 2.sub.-- .theta..sub.-- (.degree.) Cu 3.6 7.3 13.7 14.5 17.1 21.) 23.6 26.7 d space 24.2 12.2 6.5 6.1 5.2 4.2 3.8 3.3 ______________________________________The invention also relates to methods of preparing the above compound, pharmaceutical compositions containing the above compound, and methods of treating bacterial infections by administering the above compound.Type: GrantFiled: January 30, 1998Date of Patent: June 27, 2000Assignee: Pfizer Inc.Inventors: Timothy Norris, James J. McGarry, Douglas J. M. Allen
-
Patent number: 5914329Abstract: The dimesylate salt of cis-1-(3-ethoxyphenyl)-1-(4-phenylpiperazin-1-yl)4-methyl-cyclohexane has superior properties and is useful to treat physiological disorders associated with an excess of neuropeptide Y.Type: GrantFiled: November 18, 1997Date of Patent: June 22, 1999Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Lyle R. Brostrom, Alireza S. Kord, Laurie A. Whipple
-
Patent number: 5760009Abstract: A crystalline monohydrate of (3.beta.,5.alpha.,25R)-3-?(.beta.-D-cellobiosyl)oxy!spirostan-11-one that is useful as a hypocholesterolemic or antiatherosclerosis agent.Type: GrantFiled: October 19, 1995Date of Patent: June 2, 1998Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Harry A. Watson, Jr., Jonathan B. Zung
-
Patent number: 5312925Abstract: The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indole-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.Type: GrantFiled: September 1, 1992Date of Patent: May 17, 1994Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Frank R. Busch, Sabeto A. DiRoma, Dennis M. Godek
-
Patent number: 5248699Abstract: This invention relates to a novel crystalline polymorphic form of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4 -tetrahydro-N-methyl-1-naphthalenamine hydrochloride, and to a method for preparing it.Type: GrantFiled: August 13, 1992Date of Patent: September 28, 1993Assignee: Pfizer Inc.Inventors: Robert J. Sysko, Douglas J. M. Allen
-
Patent number: 5036099Abstract: Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide having advantageous properties for formulation as an analgesic or antiinflammatory agent.Type: GrantFiled: July 18, 1989Date of Patent: July 30, 1991Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Brian T. O'Neill
-
Patent number: 4997949Abstract: Crystalline 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole dihydrochloride trihydrate having advantageous properties.Type: GrantFiled: April 20, 1989Date of Patent: March 5, 1991Assignee: Pfizer Inc.Inventors: Douglas J. M. Allen, Berkeley W. Cue